Axon Enterprise, Inc (NASDAQ:AXON – Get Free Report) CRO Cameron Brooks sold 1,242 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $500.00, for a total value of $621,000.00. Following the transaction, the executive owned 49,710 shares in the company, valued at approximately $24,855,000. This trade represents a 2.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Axon Enterprise Price Performance
Shares of NASDAQ:AXON opened at $447.59 on Thursday. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49. The stock’s fifty day simple moving average is $409.55 and its two-hundred day simple moving average is $490.06. Axon Enterprise, Inc has a 1-year low of $339.01 and a 1-year high of $885.91. The stock has a market cap of $36.08 billion, a PE ratio of 179.76, a price-to-earnings-growth ratio of 8.23 and a beta of 1.45.
Axon Enterprise (NASDAQ:AXON – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.01. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The business had revenue of $807.35 million for the quarter, compared to analysts’ expectations of $778.91 million. During the same period last year, the business earned $1.47 EPS. The business’s revenue was up 33.7% on a year-over-year basis. As a group, analysts forecast that Axon Enterprise, Inc will post 1.82 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Get Our Latest Research Report on AXON
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of the business. Rathbones Group PLC lifted its position in Axon Enterprise by 11.1% in the 1st quarter. Rathbones Group PLC now owns 50,908 shares of the biotechnology company’s stock worth $21,620,000 after buying an additional 5,100 shares during the last quarter. Pine Valley Investments Ltd Liability Co lifted its position in Axon Enterprise by 58.0% in the 1st quarter. Pine Valley Investments Ltd Liability Co now owns 4,901 shares of the biotechnology company’s stock worth $2,081,000 after buying an additional 1,799 shares during the last quarter. Parallel Advisors LLC lifted its position in Axon Enterprise by 7.2% in the 1st quarter. Parallel Advisors LLC now owns 1,095 shares of the biotechnology company’s stock worth $465,000 after buying an additional 74 shares during the last quarter. NewEdge Advisors LLC lifted its position in Axon Enterprise by 32.4% in the 1st quarter. NewEdge Advisors LLC now owns 5,315 shares of the biotechnology company’s stock worth $2,257,000 after buying an additional 1,301 shares during the last quarter. Finally, Foguth Wealth Management LLC. bought a new stake in Axon Enterprise in the 1st quarter worth approximately $541,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.
Key Axon Enterprise News
Here are the key news stories impacting Axon Enterprise this week:
- Positive Sentiment: Axon’s Connected Devices business is showing renewed momentum, with revenue up 33% as demand accelerated for TASER 10, Axon Body 4, and platform solutions. That reinforces the company’s growth story and suggests upside if product adoption continues. AXON’s Connected Devices Growth Picks Up: More Upside to Come?
- Positive Sentiment: Analyst coverage remains favorable, with reports saying the average brokerage recommendation is a Buy / Moderate Buy and one major bank maintained a $705 price target. That kind of support can help investor confidence, especially after a recent selloff. Analyst Reiterates Buy on AppLovin, Maintains $705 Price Target on Axon-Driven Long-Term Growth Outlook
- Neutral Sentiment: Articles revisiting whether investors should trust brokerage ratings are more commentary than catalyst, so they are unlikely to move the stock on their own. AXON’s Connected Devices Growth Picks Up: More Upside to Come?
- Negative Sentiment: Insider sales by executive Patrick Smith and CRO Cameron Brooks may weigh on sentiment, even though the transactions were disclosed under pre-arranged trading plans. Investors often view insider selling cautiously when a stock has already been volatile. Patrick Smith Sells 20,000 Shares of Axon Enterprise (NASDAQ:AXON) Stock
- Negative Sentiment: Competitive pressure may be increasing as Motorola Solutions moves further into counter-drone and public safety technology, potentially challenging Axon’s future expansion in adjacent markets. Axon Enterprise Weighs Motorola Counter Drone Deal For Public Safety Future
Axon Enterprise Company Profile
Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.
Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.
See Also
- Five stocks we like better than Axon Enterprise
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.
